Autoimmune Diseases  >>  Tresiba (insulin degludec)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tresiba (insulin degludec) / Novo Nordisk
Basal21, NCT02360254: Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes

Completed
N/A
26
Europe
Insulin degludec, Tresiba
University of Padova, Azienda Ospedaliera di Padova
Type 1 Diabetes Mellitus
01/16
02/16
NCT02117622: A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Completed
N/A
1056
RoW
insulin degludec
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
04/17
04/17

Download Options